Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer

Phase 4

Completed

Conditions: Prostate Cancer Metastatic

Interventions: Drug: CABAZITAXEL XRP6258
Drug: Prednisone
Drug: Prednisolone

First Posted Date: 2014-02-28

Last Posted Date: 2016-06-02

Lead Sponsor: Sanofi

Target Recruit Count: 10

Registration Number: NCT02074137

Locations: 🇮🇳
Investigational Site Number 356003, New Delhi, India
🇮🇳
Investigational Site Number 356005, Kollkata, India
🇮🇳
Investigational Site Number 356002, Trivandrum, India

Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma

Phase 1

Completed

Conditions: Stage IV Adult Diffuse Large Cell Lymphoma
Stage III Adult Diffuse Large Cell Lymphoma
Stage I Adult Diffuse Large Cell Lymphoma
Contiguous Stage II Adult Diffuse Large Cell Lymphoma
Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma

Interventions: Drug: Carfilzomib
Biological: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin hydrochloride
Drug: Vincristine sulfate
Drug: Prednisone
Drug: Pegfilgrastim
Drug: Acyclovir

First Posted Date: 2014-02-27

Last Posted Date: 2024-05-29

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 48

Registration Number: NCT02073097

Locations: 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Oprozomib
Drug: Melphalan
Drug: Prednisone

First Posted Date: 2014-02-27

Last Posted Date: 2017-05-02

Lead Sponsor: Amgen

Target Recruit Count: 9

Registration Number: NCT02072863

Locations: 🇮🇹
Hospital City of Health and Science of Turin, Hematology 1 Division, Turin, Italy
🇮🇹
Ospedale Oncologico Regionale, Rionero in Vulture, Potenza, Italy
🇳🇱
Erasmus MC, Department of Hematology, Rotterdam, Netherlands

and more 5 locations

Cardiovascular Risk Following Conversion to Full Dose Myfortic® and Neoral® Two-hour Post Level Monitoring

Phase 4

Withdrawn

Conditions: Kidney Transplantation
Kidney Transplant Recipients
Cardiovascular Disease
Cardiovascular Outcomes

Interventions: Drug: Myfortic®
Drug: Neoral®
Drug: Cellcept®
Drug: Prednisone

First Posted Date: 2014-02-10

Last Posted Date: 2017-01-09

Lead Sponsor: University of Saskatchewan

Registration Number: NCT02058875

Locations: 🇨🇦
St. Paul's Hospital, Saskatoon, Saskatchewan, Canada
🇨🇦
Kidney Health Center, Regina, Saskatchewan, Canada

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL

Phase 1

Completed

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: Venetoclax
Drug: Cyclophosphamide
Drug: Obinutuzumab
Drug: Rituximab
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2014-02-05

Last Posted Date: 2020-06-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 267

Registration Number: NCT02055820

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇦🇺
Royal Melbourne Hospital, Parkville, Victoria, Australia
🇦🇹
Medizinische Universität Wien, Wien, Austria

and more 49 locations

Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma

Phase 2

Terminated

Conditions: Acute Lymphocytic Leukemia
Adult Lymphoblastic Lymphoma

Interventions: Drug: DNR
Drug: VCR
Drug: PEG-asp
Drug: CTX
Drug: Prednisone
Drug: Liposomal AraC
Drug: MTX
Drug: LCV
Drug: AraC
Drug: Etoposide
Drug: Dasatinib
Drug: Rituximab
Drug: Hydrocortisone

First Posted Date: 2014-01-23

Last Posted Date: 2022-05-02

Lead Sponsor: University of California, San Diego

Target Recruit Count: 31

Registration Number: NCT02043587

Locations: 🇺🇸
UCSD, Division of Blood and Marrow Transplantation, Moores Cancer Center, La Jolla, California, United States
🇺🇸
Hematological Malignancies/Stem Cell Transplantation Unit, David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

and more 1 locations